# A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

> **NCT06920004** · PHASE3 · RECRUITING · sponsor: **argenx** · enrollment: 218 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy
- CIDP
- CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **BIOLOGICAL:** empasiprubart
- **BIOLOGICAL:** IVIg
- **OTHER:** empasiprubart-placebo
- **OTHER:** IVIg-placebo

## Key facts

- **NCT ID:** NCT06920004
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-09
- **Final completion:** 2030-09
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920004, "A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06920004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*